GT Biopharma doses first patient in Phase 1 trial of GTB-3650 for hematologic malignancies

GT Biopharma, Inc.

GTB-3650 is a second-generation TriKE using camelid nanobody technology to improve potency and binding affinity.
Phase 1 dose-escalation trial will enroll up to ~14 patients (7 cohorts) with r/r CD33+ AML and MDS.
Initial clinical data from the study expected in 2025.
Trial assesses safety, PK, PD, NK cell expansion, and clinical activity over up to 4 months of treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.